We’re excited to announce that our multimodal immune profile score (IPS) algorithmic test is now available for RUO. IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. IPS is a pan-cancer, laboratory developed test that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate an IPS from 0-100 and a classification of either IPS-Low or IPS-High. Learn more: https://tempus.co/3y7ylHp
Tempus AI
Biotechnology Research
Chicago, IL 74,292 followers
Tempus is advancing data-driven precision medicine with the practical application of AI in healthcare. It’s About Time.
About us
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).
- Website
-
http://www.tempus.com
External link for Tempus AI
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Chicago, IL
- Type
- Privately Held
- Founded
- 2015
Locations
Employees at Tempus AI
Updates
-
We’re looking for a Molecular Technologist to join our laboratory team in Chicago. The role will work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory. Learn more and apply here: https://tempus.co/3zKkqru #NowHiring #ChicagoJobs
-
We’re excited to share that we have reached a major milestone of publishing our 500th publication. In the last eight years, we have invested in rigorous scientific research to validate our diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by our multimodal data library. Learn more: https://tempus.co/462AT68
-
We’re excited to announce that our PurIST℠ algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurIST℠ PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms. Learn more: https://tempus.co/3zx5QmZ
-
We’re excited to announce that the Centers for Medicare & Medicaid Services has granted Advanced Diagnostic Laboratory Test (ADLT) status for our xT CDx test. xT CDx is the first FDA-approved next-generation sequencing assay to perform matched normal sequence analysis to provide tumor mutation profiling for patients with solid organ neoplasms. Learn more: https://tempus.co/3L9vnVO
-
As #PrideMonth comes to a close, we want to extend a massive thank you to our Pride Employee Resource Group that executed a month full of inspiring, thought-provoking, and fun activities so we could celebrate our LGBTQIA employees and allies. We’re grateful for this dedicated month to honor the history, culture, and contributions of LGBTQIA individuals.
-
We’re thrilled to announce that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our ECG-AF device that uses AI to help identify patients who may be at an increased risk of atrial fibrillation/flutter (AF). This is the first FDA clearance for an AF indication in the category known as “cardiovascular machine learning-based notification software” and paves the way for physicians to use this innovative algorithm in the care of their patients. Read more: https://tempus.co/3RFqKqj
-
We’re excited to be partnering with United Therapeutics Corporation to develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension (PH). Together with UT, we plan to implement this prospective clinical study at up to 60 centers to evaluate the clinical impact of this technology and gain new insights into the detection and diagnosis of PH. Read more: https://tempus.co/3XFC0a4
-
Join us on Tuesday, July 9th at 1:00 p.m. CT for an upcoming #webinar, “Harnessing the Power of AI: Optimizing Workflows & Enhancing Testing Across the Cancer Care Continuum.” Tempus speakers, Ezra Cohen, MD, FASCO, Kate Sasser, PhD, and Halla Nimeiri, MD, will discuss the latest advancements in our AI & technology, as well as our recent expansion into the MRD and monitoring space, which are helping to streamline efficiencies in clinical practices and research processes. Register here: https://tempus.co/4ctgf1f
-
An analysis of 15,000 de-identified Tempus nP PGx patient records, recently published in Molecular Psychiatry, revealed that 65% of patients had CYP2D6 and CYP2C19 phenotypes actionable for medication prescribing. More than half of the top 25 most frequently prescribed medications in psychiatry are metabolized by CYP2D6 and CYP2C19, emphasizing the importance of these findings. Access the full manuscript here: https://tempus.co/3VMYjZW